Identifying Efficacious Thresholds for Bleeding Risk Reduction in Relation to Factor IX (FIX) Levels in Hemophilia B Patients Receiving IDELVION

被引：0
|
作者：
Fosser, C. [1 ]
Roberts, J. [2 ]
Tortorici, M. [2 ]
Jacobs, I. [2 ]
Sidhu, J. [2 ]
机构：
[1] Cytel, Cambridge, MA USA
[2] CSL Behring, King Of Prussia, PA USA
来源：
JOURNAL OF PHARMACOKINETICS AND PHARMACODYNAMICS | 2017年 / 44卷
关键词：
D O I：
暂无
中图分类号：
R9 [药学];
学科分类号：
1007 ;
摘要：
M-010
引用
收藏
页码：S15 / S15
页数：1
相关论文
共 50 条
  • [21] PERIOPERATIVE BLEEDING PROPHYLAXIS USING PURIFIED FACTOR-IX CONCENTRATE DURING SURGERY ON 2 PATIENTS WITH HEMOPHILIA-B
    PABINGER, I
    KYRLE, P
    LACK, W
    FUNOVICS, J
    THROMBOSIS AND HAEMOSTASIS, 1993, 69 (06) : 1284 - 1284
  • [22] Bleeding Episodes in Patients With Haemophilia B Receiving Prophylactic Factor IX Treatment: A Systematic Review and Meta-Analysis
    Franchini, Massimo
    Pasca, Samantha
    Mengoli, Carlo
    Focosi, Daniele
    Mannucci, Pier Mannuccio
    HAEMOPHILIA, 2025, 31 (02) : 173 - 186
  • [23] Trial in progress: Disease characteristics of haemophilia B in patients receiving standard-of-care prophylactic factor IX (FIX) replacement therapy
    O'Brien, M. P.
    Pipe, S. W.
    Pierce, G. F.
    Sabin, L.
    Chalothorn, D.
    Chan, K. -C.
    Tuckwell, K.
    Deshmukh, K.
    Reinhardt, R.
    Haagensen, A.
    Walsh, L.
    Gutstein, D. E.
    HAEMOPHILIA, 2024, 30 : 78 - 79
  • [24] DANAZOL FAILS TO INCREASE FACTOR-VIII OR FACTOR-IX LEVELS IN A DOUBLE-BLIND CROSSOVER STUDY OF PATIENTS WITH HEMOPHILIA-A AND HEMOPHILIA-B
    NUGENT, DJ
    BRAY, GL
    COUNTS, RB
    CLEMENTS, MJ
    THOMPSON, AR
    BRITISH JOURNAL OF HAEMATOLOGY, 1986, 64 (03) : 493 - 502
  • [25] Assessment of anti-Factor IX (FIX) antibodies in hemophilia B patients with an immunoassay which detects non-inhibitor and inhibitory antibodies. Correlation with FIX genotype.
    Rup, B
    Leitermann, K
    Jezuit, M
    Sommer, S
    BLOOD, 1996, 88 (10) : 1286 - 1286
  • [26] Analysis of clinical target joint bleeding on prophylactic regimens with recombinant Factor IX Fc fusion protein in patients with severe hemophilia B
    Powell, Jerry S.
    Perry, David
    Baker, Ross I.
    Shapiro, Amy
    Manco-Johnson, Marilyn J.
    Potts, James
    Robinson, Brian
    Mei, Baisong
    Pierce, Glenn F.
    HAEMOPHILIA, 2014, 20 : 94 - 94
  • [27] Stable and durable factor IX levels in patients with hemophilia B over 3 years after etranacogene dezaparvovec gene therapy
    von Drygalski, Annette
    Gomez, Esteban
    Giermasz, Adam
    Castaman, Giancarlo
    Key, Nigel S.
    Lattimore, Susan U.
    Leebeek, Frank W. G.
    Miesbach, Wolfgang A.
    Recht, Michael
    Gut, Robert
    Dolmetsch, Ricardo
    Monahan, Paul E.
    Le Quellec, Sandra
    Pipe, Steven W.
    BLOOD ADVANCES, 2023, 7 (19) : 5671 - 5679
  • [28] Reduced dose and frequency of NONACOG BETA PEGOL compared to recombinant factor IX and plasma-derived FIX in treatment of bleeding episodes and surgery in hemophilia B patients using population pharmacokinetic modelling and simulations
    Collins, P.
    Colberg, T.
    Watson, E.
    Moss, J.
    HAEMOPHILIA, 2012, 18 : 23 - 23
  • [29] The Bleeding Tendency In Relation To Predicted FVIII Activity Levels In Severe Hemophilia A Patients Treated With Recombinant Factor VIII Fc Fusion Protein
    Pasi, John
    Potts, James
    Li, Shuanglian
    Wang, Ping
    Kulke, Sarah
    Pierce, Glenn F.
    Jiang, Haiyan
    BLOOD, 2013, 122 (21)
  • [30] Assessment of joint bleeding and target joints in patients with severe or moderately severe hemophilia B (factor IX ≤ 2%) receiving prophylaxis with rIX-FP in the PROLONG-9FP clinical trial program
    Laws, Hans-Juergen
    Fukutake, Katsuyuki
    Lopez-Fernandez, Maria Fernanda
    Li, Yanyan
    Seifert, Wilfried
    Tagliaferri, Annarita
    EUROPEAN JOURNAL OF HAEMATOLOGY, 2023, 111 (02) : 293 - 299
12345